The DMTC Medical Countermeasures Program has featured the collaboration with Microbio in the 2019 Annual Report. The collaboration aims to refine InfectID to diagnose seven security sensitive biological agents (SSBAs) without culture, so the technology can be used in field deployable clinical settings.

https://issuu.com/dmtc-ltd/docs/dmtc_annual_report_2019 (see page 39)

Register your interest

InfectID is evolving rapidly. Fill in the form to keep up with product developments, including the release of Microbio's COVID-19 replicating virus assay.
  • This field is for validation purposes and should be left unchanged.